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Abstract 
 
Background: Preventive therapy is a risk reduction option for women who have an increased risk of 
breast cancer. The effectiveness of preventive therapy to reduce breast cancer incidence depends on 
adequate levels of uptake and adherence to therapy. We aimed to systematically review articles 
reporting uptake and adherence to therapeutic agents to prevent breast cancer among women at 
increased risk, and identify the psychological, clinical and demographic factors affecting these 
outcomes. 
 
Design: Searches were performed in PubMed, CINAHL, EMBASE, and PsychInfo, yielding 3851 
unique articles. Title, abstract and full text screening left 53 articles, and a further 4 studies were 
identified from reference lists, giving a total of 57. This review was prospectively registered with 
PROSPERO (CRD42014014957). 
 
Results: Twenty four articles reporting 26 studies of uptake in 21,423 women were included in a 
meta-analysis. The pooled uptake estimate was 16.3% (95% CI, 13.6-19.0), with high heterogeneity 
(I^2=98.9%, p<0.001). Uptake was unaffected by study location or agent, but was significantly higher 
in trials (25.2% [95% CI, 18.3-32.2]) than in non-trial settings (8.7% [95% CI, 6.8-10.9]) (p<0.001). 
Factors associated with higher uptake included having an abnormal biopsy, a physician 
recommendation, higher objective risk, fewer side-effect or trial concerns, and older age. Adherence 
(day-to-day use or persistence) over the first year was adequate. However, only one study reported a 
persistence of ≥80% by 5-years.  Factors associated with lower adherence included allocation to 
tamoxifen (vs. placebo or raloxifene), depression, smoking, and older age. Risk of breast cancer was 
discussed in all qualitative studies.   
Conclusions: Uptake of therapeutic agents for the prevention of breast cancer is low, and long-term 
persistence is often insufficient for women to experience the full preventive effect. Uptake is higher in 
trials, suggesting further work should focus on implementing preventive therapy within routine care.  
Key words: Preventive therapy, chemoprevention, decision-making, adherence, uptake, medication 
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Key messages 
 
In this systematic review of studies investigating decision-making in the context of breast cancer 
preventive therapy, we observed low uptake of all agents and poor long-term persistence. Our meta-
analysis including over 21,000 women demonstrated that only 1 in 6 eligible women decided to take 
preventive therapy. Persistence for 5-years was low, limiting the preventive effect in these women.  
 
 
Introduction 
 
Breast cancer is the most commonly diagnosed cancer in women, with an estimated 1.67 million new 
cases diagnosed worldwide in 2012.[1] Over 500,000 deaths are recorded each year, making it the 
leading cause of cancer death in women.[1] It is expected that one in 8 US women will be diagnosed 
with the disease in their lifetime.[2] A decline in breast cancer mortality has been observed over the 
last 40 years,[3,4] although incidence continues to rise,[5,6] particularly in developing countries.[7] A 
number of factors have been associated with an increased risk of developing breast cancer,[8] 
including family history which accounts for approximately 5-10% of all breast cancers.  
Preventive therapy is a risk reduction option for women who have an increased risk of breast 
cancer. Selective Estrogen Receptor Modulators (SERMs) have been extensively tested, and trials of 
alternative agents are ongoing. A meta-analysis of 10-year individual-level data from nine randomized 
SERM trials demonstrated a 38% reduction in overall breast cancer incidence and a 51% reduction in 
estrogen receptor positive (ER+) tumours.[9] The preventive effect of tamoxifen can last at least 20 
years.[10] Women taking SERMs have more venous thromboembolic events and more endometrial 
cancers.[9] Menopausal symptoms such as hot flashes and vaginal dryness are also more common 
among women taking SERMs, which can affect tolerability.[11]  
The effectiveness of preventive therapy to reduce breast cancer incidence at a population level 
depends on adequate levels of uptake and adherence to therapy. The discovery and testing of new 
agents also relies on acceptability to the population. An estimated 2 million US women and 500,000 
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UK women have favourable cost-benefit profiles for the prophylactic use of tamoxifen.[12,13] 
However, a meta-analysis of five studies reporting uptake data in non-trial settings found a mean 
uptake of just 14.8% among women offered the opportunity to take preventive therapy.[14] Trial data 
were not included in this review. Independent studies and narrative reviews have also raised concern 
about the low levels of long-term adherence to preventive therapy,[11,15,16] but no systematic 
synthesis has been done.   
To make recommendations for future research and clinical practice, this review aims to 
synthesise the available quantitative data on uptake of preventive therapy and adherence among 
women who have an increased risk of breast cancer in either trial or non-trial settings. To aid the 
development of behavioural interventions, we aimed to identify the socio-demographic, clinical and 
psychological factors associated with uptake and adherence. Qualitative studies were also included in 
this investigation to supplement our understanding of women’s decision-making in this context. 
 
Methods 
 
Search Strategy 
We searched for quantitative articles reporting uptake and adherence to medications used for the 
purpose of preventing primary breast cancer, and quantitative and qualitative articles reporting factors 
affecting these decisions. Adherence included either adequate day-to-day use of the medication or 
persistence with it over time. In November, 2014 separate searches were performed in PubMed, 
CINAHL, EMBASE, and PsychInfo (see Supplementary Appendix 1 for example search terms). The 
review was prospectively registered on the PROSPERO database[17] (registration number: 
CRD42014014957). PRISMA guidelines were followed throughout[18] (Supplementary Appendix 2).  
 
Article selection  
The inclusion criteria were peer-reviewed studies: in English language; including women aged 18 
years or older; reporting quantitative or qualitative data; including at least one aspect of medication 
use (uptake, day-to-day adherence with prescription guidelines and/or persistence with the medication 
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over time); and using or testing the agent for the purpose of breast cancer prevention. Qualitative 
studies had to investigate eligible women’s perceptions of preventive therapy and explanations for 
their decisions associated with chemoprevention. The exclusion criteria were studies including 
women affected by breast cancer (including ductal carcinoma in situ), agents where the primary 
purpose was not breast cancer prevention, hypothetical rates of adherence, men only, clinician 
perspectives, non-peer reviewed studies, conference abstracts, reviews, interventions not involving 
oral agents and commentaries and letters not including empirical data. No restriction was placed on 
publication dates or study design. 
After removing duplicates, two authors (SS, AF) used the inclusion and exclusion criteria to 
review half of the titles and abstracts each. The same authors checked the excluded articles of the 
other person to ensure sensitivity. A similar process was undertaken for the full texts. The remaining 
article’s reference lists were examined to identify studies not included in our search. The articles 
included in the meta-analysis were decided by mutual discussion (SS, IS).  
 
Data extraction 
Data were extracted by one author using electronic database software (SS). Guided by the Cochrane 
Handbook for Systematic Reviews Handbook, two authors (SS, IS) agreed on the appropriate 
variables to be extracted,[19] and this was piloted by SS. The variables extracted included study 
authors, date, location, design, analysis (qualitative), context (trial / non-trial), sample size, sample 
age, uptake levels, adherence levels, adherence type (day-to-day / persistence), factors tested for an 
association with adherence and qualitative themes. 
 
Quality assessment 
The Mixed Methods Appraisal Tool (MMAT) can be used to assess study quality in mixed study 
reviews.[20] The MMAT is reliable,[21] and has been used in reviews of decision-making in the 
context of cancer.[22,23] Each study is screened using two items related to the quality of the 
objectives, and the extent to which the data address the objectives. Study designs are classified as: 1) 
qualitative; 2) quantitative randomized controlled trials 3) quantitative non-randomized; 4) 
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quantitative descriptive; and 5) mixed methods. Study designs 1-4 each have four of their own quality 
assessment items. Mixed methods studies are rated using three items, and then both sets of items for 
the two types of data reported (e.g. quantitative non-randomized and qualitative). All items are rated 
as ‘yes’, ‘no’ or ‘can’t tell’, with one point awarded for each ‘yes’ response. Scores range from 0-4, 
with mixed method studies only able to score as highly as their lowest score for each study design.  
One researcher (SS) assessed the quality of all included articles using the MMAT, and 20% of these 
were randomly selected and checked by a second researcher (AF) to ensure agreement. Discrepancies 
were resolved through discussion. MMAT scores were assessed at the study level and so were not 
necessarily associated with the quality of uptake and adherence data. To overcome this limitation we 
created a single subjective evaluation assessing the extent to which the article contributed to our 
review.  
 
Analysis 
Random effect meta-analysis was used to allow for heterogeneity across uptake studies. Data were 
analysed in STATA 13.1 using the “metaprop” command. Study heterogeneity was assessed with Q 
statistics and I2 estimations.[24] Results are plotted as a proportion (%) of women who have taken up 
preventive therapy with corresponding 95% confidence intervals and all P-values are two-sided. A  
quantitative synthesis of the adherence data was not possible due to differences in the data collection 
measure (e.g. pill count, clinical assessment, Medication Events Monitoring Systems) and type of 
adherence data collected (e.g. day-to-day, persistence or both).  Therefore a narrative synthesis 
describing these data was done. A narrative synthesis of the qualitative data was also performed.  
 
Results 
 
The initial search yielded 4743 articles, of which 3850 remained after removing duplicates (Figure 1). 
Title screening led to 3345 exclusions, and a further 320 articles were removed after reviewing the 
remaining abstracts. One hundred eighty five full text articles were assessed and 53 met inclusion / 
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exclusion criteria. The reference lists of the remaining 53 articles were searched, and a further 4 
manuscripts were identified. A total of 57 articles are included in the review.  
 
Characteristics of included studies 
Thirty one articles reported uptake (Table 1) and 23 reported adherence (Table 2). Seventeen papers 
(30%) scored the maximum of 4/4 on the MMAT, the majority of which were non-randomized 
quantitative studies.[25–41] Four studies (7%) met only one of the four assessment criteria,[42–45] all 
of which were randomized quantitative studies. Only three studies (5%) were given the highest rating 
of 4/4 using our subjective assessment,[34,35,40] and five (9%) scored just 1/4.[46–50] The mean 
quality score using the MMAT was 3.1 out of 4 compared with 2.5 out of 4 using the subjective 
assessment (Supplementary Tables 1-3).  
Using MMAT categories, 34 studies used a non-randomized quantitative design[28–41,50–
69], 16 used a randomized quantitative design,[25–27,42–45,47–49,70–75] 5 studies were 
qualitative[46,76–79] and 2 were mixed-methods.[80,81] Among the qualitative and mixed methods 
studies, 5 reported interview data[46,77,79–81] and 2 reported focus group data.[76,78] The majority 
of quantitative studies (N=36) were from trials,[25–27,29,31–37,40,44–
53,55,56,58,61,62,64,66,70,71,73–75,80] with 20 studies reporting non-trial data from clinics, cohorts 
and national surveys,[30,38,39,41–43,54,57,59,60,63,65,67–69,72,76,78,79,81] and 2 studies 
included both trial and non-trial data.[28,77] The majority of studies (N=50) reported data on SERMs, 
with the remaining studies using aromatase inhibitors (AIs) (N=6),[29,37,40,52,61,71] aspirin,[48] 
lovastatin[50] and luteinising-hormone-releasing hormone (LHRH).[53] 
The sample size of the quantitative studies ranged from 30[50,72] to 19,471[26,27], and the 
qualitative studies ranged from 2[46] to 51[80]. The studies were from a range of countries, including 
30 from the US,[26–28,31,33,34,36,41–44,46,48–51,54–56,60,65–67,69,72,76,78–80] 8 from the 
UK[32,52,53,58,73–75,81] 3 from Italy,[40,62,64] 3 from Canada,[63,68,77] and one from each of 
Germany,[37] Australia,[30] China,[57] France[61] and Finland.[45] Eight studies were 
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international.[29,38,39,47,59,64,70,71] Age was variably reported, but the lowest recorded was a 
median of 39 years[30] and the highest was a mean of 67 years.[34] 
 
Uptake of breast cancer preventive therapy 
For the meta-analysis, 24 articles reporting 26 studies of uptake in 21423 women were included. 
Seven articles reporting uptake were not included because more complete or similar data were 
available in another study.[30,33,39,42,56,59,65] Uptake ranged from 0%[44,57] to 54.9%.[80] The 
pooled uptake estimate was 16.3% (95% CI, 13.6-19.0), with high heterogeneity (I^2=98.9%, 
P<0.001) (Figure 2). Uptake was higher in trials (25.2% [95% CI, 18.3-32.2]) than in non-trial 
settings (8.7% [95% CI, 6.8-10.9]), and this difference was statistically significant (P<0.001). Uptake 
was unaffected by agent and study location (Supplementary Figures 1 and 2). 
Fourteen of the uptake studies tested at least one predictor of uptake within the study (Table 
4). Clinical factors associated with higher uptake in more than one study included having an abnormal 
breast biopsy[28,69] and receiving a physician recommendation.[28,56] Higher clinically assessed 
risk was associated with higher uptake in two studies,[69,81] but this effect was not consistent.[56,62] 
Clinical factors reaching statistical significance in one study included having all questions answered 
by a physician, perceiving that the clinician supported their understanding of preventive therapy,[62] 
and not having a BRCA mutation.[81] Previous experience of hot flashes was associated with lower 
uptake in one study,[66] but there was no association in another.[56] There was no association 
between uptake and other clinical factors including the number of family members 
diagnosed,[40,56,69] experiencing a breast biopsy,[28,69] previous hysterectomy[56,66,69] and 
menopausal status.[66,69] 
Lower uptake was consistently observed in women concerned about contradictions with 
estrogen.[56,66] Greater concern about side-effects was associated with lower uptake in two 
studies,[28,66] although no relationship was found in another.[33] Statistically significant patient 
factors implicated in only one study included intrusive thinking,[28] perceived vulnerability,[28] 
worry about breast cancer,[62] concern at the experimental nature of trials,[66] personal desire to 
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participate in a trial,[55] perceived value of trials,[55] perceived inconvenience of the trial,[55] the 
frequency of clinic visits needed[66] and alcohol consumption.[62] There was mixed or no evidence 
for several other patient factors (Table 4). 
No demographic factors were associated with uptake in more than one study. Country of 
residence was associated with uptake in a single study,[38] with lower uptake in France, Italy, 
Holland, and Norway. There was inconsistent or no evidence for age[40,56,62,66,69,81], race,[56] 
education,[40,56,62,66] income,[66] employment status,[33] insurance,[56,66] parity[69] and 
cost.[33,56,66] 
 
Adherence to breast cancer preventive therapy 
All adherence studies were from trial data (Table 2). Studies investigating adherence mainly reported 
data on persistence (N=18).[25–27,31,32,36,40,45,47,50,51,58,64,70,71,73–75] Four reported data on 
day-to-day adherence,[29,48,49,58] and two used a hybrid measure of day-to-day adherence and 
persistence.[34,35] Adherence measurement varied. Eight studies reported pill count 
data,[29,34,40,47–50,70] six noted adherence during a clinical visit,25,31,35,36,51,64 five included 
self-report data,[32,71,73–75] one used Medication Even Monitoring Systems (MEMS),[58] and three 
did not report how adherence was measured.[26,27,45] Eight studies reported data from a five year 
follow-up,[25,27,32,36,45,58,64,70,74,75] and the shortest end-point was 3 months.[71]  
Overall, studies suggested day-to-day adherence to preventive therapy was high, although all 
data were recorded within two years of initiating therapy.  Day-to-day adherence was particularly high 
at two year follow-up in the MAP.3 exemestane trial (median, 97%)[29] and in a pilot trial of 
raloxifene with omega-3 followed up for one year (96%).[49] A study using MEMS also suggested 
high rates of day-to-day adherence, at least in the first six months of therapy.[58] High rates of day-to-
day adherence were reported over a 6 month period in an aspirin trial (87%).[48] The two studies 
combining day-to-day adherence and persistence data reported high rates, although this was likely to 
decline over time.[35] One study only enrolled women who were adherent at baseline, which could 
bias subsequent reports.[34]   
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Among studies reporting 5-year follow-up data, persistence ranged from 61.1% in the 
tamoxifen arm of the STAR trial[27] to 80.8% in both arms of the Royal Marsden trial.[74] However, 
a lower estimate of persistence (64.5%) in the Royal Marsden trial was reported elsewhere.[75] 
Several studies indicated adequate short-term persistence, which declined over time.[25,47,73] Italian 
data from the IBIS II Anastrozole trial reported a sharp decline in persistence from 78.1% at 6 months 
to 61.3%, 41.6% and 13.9% in years one, two and three.[40]   
Eleven studies investigating either day-to-day adherence or persistence tested at least one 
predictor (Table 5). The most important clinical factor appeared to be the agent used. Five studies 
reported lower persistence to tamoxifen compared with placebo[32,74,75] and raloxifene.[36,45] Two 
studies reported lower day-to-day adherence to tamoxifen compared with placebo[35] and 
raloxifene.[34] One study showed comparable persistence between tamoxifen and placebo,[73] 
possibly due to low statistical power. Day-to-day adherence was similar between groups in a trial 
evaluating the effect of raloxifene vs. placebo and vs. omega-3 fatty acids.[49] Higher objective risk 
was associated with greater day-to-day adherence in one large study,[35] although a smaller sub-
sample of the IBIS 1 trial did not observe this effect.[58] Women with fewer depressive symptoms 
were more persistent in two studies,[31,34] but no effect was found in another.[58] There was mixed 
evidence for the relationship between persistence and use of other medications.[34,58] There was no 
evidence for the remaining clinical factors (Table 5).  
Non-smoking status was linked with higher day-to-day adherence in two studies.[35,58] One 
study suggested participants who expected to be on therapy for longer were more adherent.[34] The 
same study also demonstrated greater day-to-day adherence among those with higher verbal memory, 
although multiple other cognitive domains were tested which showed no effect.[34] There was no 
evidence for a relationship between adherence and alcohol consumption,[35] overweight[35] and 
physical activity.[35] No demographic factor was consistently associated with adherence, although 
two large studies suggested younger age was linked with higher day-to-day adherence,[34,35] and one 
suggested higher levels among the more educated.[35] There was no evidence of other socioeconomic 
disparities, as assessed by ethnicity,[34,35] employment[35] or income.[35] There was also no 
relationship between day-to-day adherence and living alone,[35] marital status[58] or parity.[58]  
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A relationship between side-effects and adherence was suggested by reports of lower 
persistence among women taking tamoxifen compared with placebo and raloxifene.[32,34–
36,45,74,75] However, the quality of side-effect assessment was poor. The primary tool for 
assessment was ‘off-therapy forms’ (OTFs) provided only to women who did not persist with the 
medication. These data are likely to be subject to attribution bias. Seven tamoxifen studies used OTFs 
to document the proportion of women who attributed their drop-outs to side-effects[31,35,45,51,73–
75] and one anastrozole trial used an OTF.[40] Data from three placebo-controlled trials reported a 
higher proportion of side-effect related drop-outs among women taking tamoxifen,[45,51,75] although 
almost half of the women stopping prematurely attributed their decision to non-medical 
factors.[51,75]  
 
Qualitative data on breast cancer preventive therapy decision-making 
The characteristics of the qualitative studies are shown in Table 3 and the extracted themes are 
presented in Table 6. All seven qualitative studies included were related to women’s attitude towards 
tamoxifen or raloxifene, and their decision to initiate preventive therapy. All studies discussed at least 
one aspect of breast cancer risk. Five studies reported that women with a heightened perceived 
personal risk were more likely to use preventive therapy,[76–80] with low perceived risk resulting 
from a sense of wellness[76] or lack of symptoms.[79] Taking preventive therapy was considered to 
be a daily reminder of one’s risk,[81] which some women preferred to deny[77] or seek alternative 
strategies.[78] A Canadian study noted unrealistic views about prevention among some women, with 
risk-reduction expectations ranging from 50-100%.[77] Three studies reported that concerns about 
side-effects were a deterrent to uptake.[77,80,81] One diverse focus group study noted a low 
awareness of preventive therapy,[76] which may be as a result of a lack of information about the 
topic[77] and poor patient-provider communication.[76] Two other studies reported a low level of 
understanding regarding the causes of breast cancer.[76,79] The use of medication for prevention was 
considered to be an important topic,[79] with women reporting concerns about drug interactions,[76] 
the ‘unnatural’ nature of medications[76,77,79] and worries that HRT would be 
contraindicated.[77,80] One high quality study reported women were reluctant to use tamoxifen 
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because they considered it to be a ‘cancer drug’ that was inextricably linked with the disease and their 
family’s history of using the drug.[81] Several trial-related factors were barriers to enrolment 
including the time commitment and the concept of randomization.[80] Altruism was a motivating 
factor for some women.[77,80] Factors mentioned in only one study can be found in Table 6.  
 
Discussion 
In this systematic review of studies investigating decision-making in the context of breast cancer 
preventive therapy, we observed low uptake of all agents and poor long-term persistence. In our meta-
analysis including over 21,000 women, only 1 in 6 women decided to take preventive therapy or enter 
a chemoprevention trial. We were unable to explain the heterogeneity observed in the model using 
pre-specified sub-group analyses comparing agent, context and location. Short-term persistence was 
high, and women demonstrated adequate use of medications on a day-to-day basis. However, 
persistence with preventive therapy for 5-years was low, limiting the preventive effect in these 
women. These data suggest future research should be directed towards supporting decision-making at 
the point of uptake, as well as ensuring mechanisms are in place to promote persistence among 
women who have initiated therapy. 
Our estimate of uptake is comparable with a previous meta-analysis reporting 15% of women 
accepted the offer of preventive therapy in five studies outside a trial setting.[14] However, sub-group 
analysis suggested uptake in clinical settings was significantly lower than this estimate. The 
difference in uptake between settings suggests issues with implementing preventive therapy within 
routine patient care. Clinician’s attitudes towards the topic of preventive therapy are not well known, 
but prescribing concerns may affect their willingness to discuss this option.[82] For example, 
tamoxifen and raloxifene are not licensed for prevention in some countries, which can dissuade 
prescribing.[82–84] Discussing medication and writing prescriptions are also unfamiliar tasks for 
many clinicians working with high risk populations. Providing appropriate support and training may 
encourage the implementation of preventive therapy into routine patient care. 
There was considerable heterogeneity in our uptake estimate, and this is likely to be a result 
of specific studies reporting high enrolment rates. The highest uptake (54.9%) was reported in a small 
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(N=51) mixed methods study, where interest may have been higher because the study protocol 
involved attendance at an interview.[80] Similarly, uptake in specific centres of the IBIS-II trial was 
high, perhaps because enrolment was only discussed with women actively seeking information about 
the trial.[71] Caution should therefore be taken when interpreting these uptake data, as they may 
include populations who are more interested in prevention than the general population. They also only 
include women who have actively sought clinician advice about their breast cancer risk. Other clinical 
groups such as those with benign breast disease,[85] dense breasts[13] and older women may meet 
risk thresholds, but are not routinely offered preventive therapy.  
 Efforts to support patient decision-making may be guided by our attempt to identify the 
factors related to higher uptake and adherence. Concerns about medication were important in both 
quantitative and qualitative studies within this review. For example, in a US study of 129 women with 
follow up at 2 and 4 months after counselling, those who were more concerned about side effects or 
were unconvinced by tamoxifen’s preventive effect were less likely to initiate therapy.[28] Other 
concerns included the perception that tamoxifen was a ‘cancer drug’ that would serve as a reminder of 
family members who had used it.[81] Mistrust of medication in general was also a common 
attitude.[77,79] These observations support a meta-analysis of the Necessity Concerns Framework, 
which showed lower adherence among patients who felt medication was an unnecessary part of their 
disease management, or among those who expressed greater concerns about the use of 
medication.[86] Attempts to correct such beliefs have had mixed results,[87–89] but several studies 
have indicated that necessity beliefs and concerns are amenable to change.[90-92]   
 Data from our review suggest receipt of a clinician recommendation may not be sufficient to 
increase uptake,[28,56] but discussions about the risks and benefits of preventive therapy are 
necessary for informed decision-making.[93] Studies suggested women making informed decisions 
were equally likely to initiate therapy. One study reported higher uptake among patients who believed 
that all their questions had been answered and that their clinician had helped them understand.[62] A 
decision-aid tested in the context of a clinical trial was also effective in supporting women’s decision-
making, without reducing uptake.[71] There is a clear demand for information about preventive 
therapy,[77] and awareness levels are low.[76] Women’s decision-making about preventive therapy 
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could benefit from patient-centred communications, which outline the risks and benefits of preventive 
therapy in a comprehensible manner.[94]  
 Studies comparing tamoxifen with placebo or raloxifene consistently reported higher drop-out 
rates among the tamoxifen arm, suggesting side-effects unique to the drug may be responsible.[32,34–
36,45,74,75] Furthermore, several studies collecting OTFs suggested over half of all drop-outs were a 
result of medication side-effects.[31,35,45,51,73–75] Clinicians counselling women with side-effects 
from tamoxifen could consider prescribing more tolerable agents with similar effectiveness.[26,27] 
While these data are somewhat useful in explaining low long-term persistence, the method is likely to 
be prone to bias. For example, women who had already chosen to cease participation may have been 
more likely to attribute their decision to a medical factor, thereby exaggerating the importance of side-
effects.  To resolve this issue, future studies are needed that prospectively collect patient-reported 
outcome data to enable comparisons between those who do and do not persist. In the meantime, 
accurate side-effect data should be conveyed to women who express concerns about 
safety.[28,66,76,77,79]   
 Due to differences in the reporting and recording of adherence, we were unable to synthesise 
the data in a meta-analysis. Despite advantages and disadvantages to different methods, there is 
currently no gold standard for defining or measuring adherence. This is a limitation in all settings in 
which medication is taken, and is not solely observed in oncology. Research is needed that not only 
seeks ways to promote adherence to these therapies, but more broadly can standardise the manner in 
which this behaviour is quantitatively assessed to allow a better comparison between studies. This 
would include agreed upon means for classifying adherence, including evidence-based thresholds for 
what can be considered adequate adherence.  The review was further limited by the low number of 
studies included in countries outside of the US and Europe. This should be addressed in light of the 
rising incidence rates in developing countries.[7] There were also insufficient reports of agents other 
than SERMs. The ongoing evaluation of next generation agents such as AIs should be accompanied 
by detailed adherence reports.  
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Conclusions 
 
In conclusion, preventive therapy uptake for the prevention of breast cancer is low, and long-term 
persistence is often insufficient for women to experience the full preventive effect. Uptake is higher in 
trial settings, suggesting further work is needed to identify the problems with implementing 
preventive therapy within routine clinical practice. Improving the communication of information 
about preventive therapy is likely to benefit women, but further research should identify additional 
factors amendable to modification to promote informed decisions related to chemoprevention.  
 
 
Funding: Smith is supported by a Cancer Research UK Postdoctoral Fellowship (C42785/A17965). 
Forster is supported by a Cancer Research UK – BUPA Cancer Prevention Postdoctoral Fellowship 
(C49896/A17429). Horne is supported by NIHR Collaboration for Leadership in Applied Research 
and Care (CLAHRC) North Thames. 
 
Disclosure: Cuzick received research funds from AstraZeneca to undertake the IBIS studies. 
Professor Cuzick has no financial ties with them. All remaining authors declare no conflict of interest.  
 
Notes: The sponsor of the study played no role in the design, collection, analysis, interpretation of the 
data, writing of the manuscript or decision to submit the manuscript for publication.  
 
 
 
 
 
 
 at U
niversity College London on D
ecem
ber 10, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
16 
References 
1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87-
108.  
2. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 
2014;64(1):52-62.  
3. Autier P, Boniol M, LaVecchia C, et al. Disparities in breast cancer mortality trends between 30 
European countries: retrospective trend analysis of WHO mortality database. BMJ 2010;341:c3620.  
4. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 
1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl 
Cancer Inst 2015;107(6): djv048 
5. Ferlay J, Héry C, Autier P, Sankaranarayanan R. Global burden of breast cancer. In: Li C, ed. 
Breast Cancer Epidemiology. Springer New York; 2010:1-19.  
6. Weir HK, Thompson TD, Soman A, et al. The past, present, and future of cancer incidence in the 
United States: 1975 through 2020. Cancer 2015;121(11):1827-1837.  
7. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries 
between 1980 and 2010: a systematic analysis. The Lancet 2011;378(9801):1461-1484.  
8. Nelson HD, Zakher B, Cantor A, et al. Risk Factors for breast cancer for women aged 40 to 49 
years: a systematic review and meta-analysis. Ann Intern Med 2012;156(9):635-648.  
9. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast 
cancer: an updated meta-analysis of individual participant data. Lancet 2013;381(9880):1827-1834. 
10. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-
term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015;16(1):67-75.  
11. Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant 
therapy and prevention. Cancer Prev Res 2011;4(9):1360-1365.  
 at U
niversity College London on D
ecem
ber 10, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
17 
12. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could 
benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95(7):526-532. 
13. Evans DGR, Warwick J, Astley SM, et al. Assessing individual breast cancer risk within the U.K. 
National Health Service breast screening program: a new paradigm for cancer prevention. Cancer 
Prev Res 2012;5(7):943-951.  
14. Ropka ME, Keim J, Philbrick JT. Patient Decisions About Breast cancer chemoprevention: a 
systematic review and meta-analysis. J Clin Oncol 2010;28(18):3090-3095.  
15. Reimers L, Crew KD. Tamoxifen vs raloxifene vs exemestane for chemoprevention. Curr Breast 
Cancer Rep 2012;4(3):207-215.  
16. Chlebowski RT, Kim J, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and 
prevention settings. Cancer Prev Res 2014;7(4):378-387.  
17. Smith SG, Wardle J, Cuzick J, et al. Medication adherence in breast cancer chemoprevention: a 
systematic review. PROSPERO. 2014. Available from 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014014957  
18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and 
meta-analyses: The PRISMA Statement. J Clin Epidemiol 2009;62(10):1006-1012.  
19. Higgins JPT, Deeks JJ, eds. Chapter 7 - Selecting studies and collecting data. In: Cochrane 
Handbook for Systematic Reviews of Interventions. Cochrane Book Series. Wiley-Blackwell; 
2008:151-186. 
20. Pluye P, Hong QN. Combining the power of stories and the power of numbers: mixed methods 
research and mixed studies reviews. Annu Rev Public Health 2014;35(1):29-45.  
21. Pace R, Pluye P, Bartlett G, et al. Testing the reliability and efficiency of the pilot: mixed methods 
appraisal tool (MMAT) for systematic mixed studies review. Int J Nurs Stud 2012;49(1):47-53. 
 at U
niversity College London on D
ecem
ber 10, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
18 
22. Puts MTE, Tu HA, Tourangeau A, et al. Factors influencing adherence to cancer treatment in 
older adults with cancer: a systematic review. Ann Oncol 2014;25(3):564-577.  
23. Puts MTE, Tapscott B, Fitch M, et al. A systematic review of factors influencing older adults’ 
decision to accept or decline cancer treatment. Cancer Treat Rev 2015;41(2):197-215.  
24. Cochran WG. The combination of estimates from different experiments. Biometrics 
1954;10(1):101-129.  
25. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: 
preliminary findings from the Italian randomised trial among hysterectomised women. The Lancet 
1998;352(9122):93-97. 
26. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of 
developing invasive breast cancer and other disease outcomes: the NSABP Study of tamoxifen and 
raloxifene (STAR) P-2 trial. JAMA 2006;295(23):2727-2741. 
27. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast 
and Bowel Project Study of tamoxifen and raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. 
Cancer Prev Res 2010;3(6):696-706.  
28. Bober SL, Hoke LA, Duda RB, et al. Decision-making about tamoxifen in women at high risk for 
breast cancer: clinical and psychological factors. J Clin Oncol 2004;22(24):4951-4957.  
29. Cheung AM, Tile L, Cardew S, et al. Bone density and structure in healthy postmenopausal 
women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the 
MAP.3 randomised controlled trial. Lancet Oncol 2012;13(3):275-284. 
30. Collins IM, Milne RL, Weideman PC, et al. Preventing breast and ovarian cancers in high-risk 
BRCA1 and BRCA2 mutation carriers. Med J Aust 2013;199(10):680-683.  
31. Day R, Ganz PA, Costantino JP. Tamoxifen and depression: more evidence from the National 
Surgical Adjuvant Breast and Bowel Project’s breast cancer prevention (P-1) randomized study. J 
Natl Cancer Inst 2001;93(21):1615-1623. 
 at U
niversity College London on D
ecem
ber 10, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
19 
32. Fallowfield L, Fleissig A, Edwards R, et al. Tamoxifen for the prevention of breast cancer: 
psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 
2001;19(7):1885-1892. 
33. Yeomans Kinney A, Vernon SW, Shui W, et al. Validation of a model predicting enrolment status 
in a chemoprevention trial for breast cancer. Cancer Epidemiol Biomark Prev 1998;7(7):591-595. 
34. Klepin HD, Geiger AM, Bandos H, et al. Cognitive factors associated with adherence to oral 
antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) 
study. Cancer Prev Res 2014;7(1):161-168.  
35. Land SR, Cronin WM, Wickerham DL, et al. Cigarette smoking, obesity, physical activity, and 
alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and 
Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res 2011;4(9):1393-1400.  
36. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life 
during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of 
tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006;295(23):2742-2751. 
37. Loehberg CR, Jud SM, Haeberle L, et al. Breast cancer risk assessment in a mammography 
screening program and participation in the IBIS-II chemoprevention trial. Breast Cancer Res Treat 
2010;121(1):101-110.  
38. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of 
preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008;122(9):2017-2022. 
39. Phillips K-A, Jenkins M, Lindeman G, et al. Risk-reducing surgery, screening and 
chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin 
Genet 2006;70(3):198-206.  
40. Razzaboni E, Toss A, Cortesi L, et al. Acceptability and adherence in a chemoprevention trial 
among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian 
Cancer Center (Italy). Breast J 2013;19(1):10-21.  
 at U
niversity College London on D
ecem
ber 10, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
20 
41. Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast 
cancer chemoprevention in 2010. Breast Cancer Res Treat 2012;134(2):875-880.  
42. Fagerlin A, Dillard AJ, Smith DM, et al. Women’s interest in taking tamoxifen and raloxifene for 
breast cancer prevention: response to a tailored decision aid. Breast Cancer Res Treat 
2011;127(3):681-688.  
43. Korfage IJ, Fuhrel-Forbis A, Ubel PA, et al. Informed choice about breast cancer prevention: 
randomized controlled trial of an online decision aid intervention. Breast Cancer Res 2013;15(5):R74.  
44. Matloff ET, Moyer A, Shannon KM, et al. Healthy women with a family history of breast cancer: 
impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal 
therapy decision making. J Womens Health 2006;15(7):843-856. 
45. Palva T, Ranta H, Koivisto AM, et al. A double-blind placebo-controlled study to evaluate 
endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen 
or placebo - a substudy for IBIS I Breast Cancer Prevention Trial. Eur J Cancer 2013;49(1):45-51.  
46. Holmberg C, Daly M, McCaskill-Stevens W. Risk scores and decision making: the anatomy of a 
decision to reduce breast cancer risk: Objective risk estimates and decision-making. J Nurs Healthc 
Chronic Illn 2010;2(4):271-280.  
47. Cuzick J, Edwards R. Drop-outs in tamoxifen prevention trials. The Lancet 1999;353(9156):930. 
48. McTiernan A, Wang CY, Sorensen B, et al. No effect of aspirin on mammographic density in a 
randomized controlled clinical trial. Cancer Epidemiol Biomarkers Prev 2009;18(5):1524-1530.  
49. Signori C, DuBrock C, Richie JP, et al. Administration of omega-3 fatty acids and raloxifene to 
women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. 
Eur J Clin Nutr 2012;66(8):878-884. 
50. Vinayak S, Schwartz EJ, Jensen K, et al. A clinical trial of lovastatin for modification of 
biomarkers associated with breast cancer risk. Breast Cancer Res Treat 2013;142(2):389-398.  
 at U
niversity College London on D
ecem
ber 10, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
21 
51. Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer 
prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Clin 
Oncol 1999;17(9):2659-2659. 
52. Evans DG, Harvie M, Bundred N, Howell A. Uptake of breast cancer prevention and screening 
trials. J Med Genet 2010;47(12):853-855.   
53. Evans DGR, Lalloo F, Shenton A, et al. Uptake of screening and prevention in women at very 
high risk of breast cancer. The Lancet 2001;358(9285):889-890. 
54. Goldenberg VK, Seewaldt VL, Scott V, et al. Atypia in random periareolar fine-needle aspiration 
affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. 
Cancer Epidemiol Biomarkers Prev 2007;16(5):1032-1034.  
55. Houlihan RH, Kennedy MH, Kulesher RR, et al. Identification of accrual barriers onto breast 
cancer prevention clinical trials: a case-control study. Cancer 2010;116(15):3569-3576.  
56. Yeomans-Kinney A, Richards C, Vernon SW, Vogel VG. The effect of physician 
recommendation on enrollment in the breast cancer chemoprevention trial. Prev Med 1998;27(5):713-
719. 
57. Kwong A, Wong CHN, Shea C, et al. Choice of management of southern chinese BRCA mutation 
carriers. World J Surg 2010;34(7):1416-1426.  
58. Maurice A, Howell A, Evans DG, et al. Predicting compliance in a breast cancer prevention trial. 
Breast J 2006;12(5):446-450.  
59. Metcalfe KA, Snyder C, Seidel J, et al. The use of preventive measures among healthy women 
who carry a BRCA1 or BRCA2 mutation. Fam Cancer 2005;4(2):97-103.  
60. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for 
breast cancer primary prevention. Ann Surg Oncol 2001;8(7):580-585. 
 at U
niversity College London on D
ecem
ber 10, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
22 
61. Pujol P, Lasset C, Berthet P, et al. Uptake of a randomized breast cancer prevention trial 
comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. Fam Cancer 
2012;11(1):77-84.  
62. Rondanina G, Puntoni M, Severi G, et al. Psychological and clinical factors implicated in decision 
making about a trial of low-dose tamoxifen in hormone replacement therapy users. J Clin Oncol 
2008;26(9):1537-1543.  
63. Taylor R. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after 
evaluation of a breast lump. Ann Fam Med 2005;3(3):242-247.  
64. Veronesi A, Pizzichetta MA, Ferlante MA, et al. Tamoxifen as adjuvant after surgery for breast 
cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with 
treatment. Tumori 1998;84(3):372-375. 
65. Waters EA, Cronin KA, Graubard BI, et al. Prevalence of tamoxifen use for breast cancer 
chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010;19(2):443-446.  
66. Yeomans-Kinney A, Vernon SW, Frankowski RF, et al. Factors related to enrollment in the breast 
cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Cancer 
1995;76(1):46-56. 
67. Layeequr Rahman R, Crawford S. Chemoprevention indication score: a user-friendly tool for 
prevention of breast cancer – pilot analysis. The Breast 2009;18(5):289-293.  
68. Metcalfe K, Ghadirian P, Rosen B, et al. Variation in rates of uptake of preventive options in 
BRCA1 and BRCA2 mutation carriers across Canada. Open Med 2007;1(2):92-98. 
69. Tchou J, Hou N, Rademaker A, et al. Acceptance of tamoxifen chemoprevention by physicians 
and women at risk. Cancer 2004;100(9):1800-1806.  
70. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast 
cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99(4):272-282.  
 at U
niversity College London on D
ecem
ber 10, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
23 
71. Juraskova I, Butow P, Bonner C, et al. Improving decision making about clinical trial participation 
– a randomised controlled trial of a decision aid for women considering participation in the IBIS-II 
breast cancer prevention trial. Br J Cancer 2014;111(1):1-7.  
72. Ozanne EM, Annis C, Adduci K, et al. Pilot trial of a computerized decision aid for breast cancer 
prevention. Breast 2007;13(2):147-154. 
73. Powles TJ, Hardy JR, Ashley SE, et al. A pilot trial to evaluate the acute toxicity and feasibility of 
tamoxifen for prevention of breast cancer. Br J Cancer 1989;60(1):126. 
74. Powles TJ, Jones AL, Ashley SE, et al. The Royal Marsden Hospital pilot tamoxifen 
chemoprevention trial. Breast Cancer Res Treat 1994;31(1):73-82. 
75. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal 
Marsden Hospital tamoxifen randomised chemoprevention trial. The Lancet 1998;352(9122):98-101. 
76. Cyrus-David MS, Strom SS. Chemoprevention of breast cancer with selective estrogen receptor 
modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer. 
Psychooncology 2001;10(6):521-533. 
77. Heisey R, Pimlott N, Clemons M, et al. Women’s views on chemoprevention of breast cancer. 
Can Fam Physician 2006;52(5):624-625. 
78. Paterniti DA, Melnikow J, Nuovo J, et al. “I’m going to die of something anyway”: women’s 
perceptions of tamoxifen for breast cancer risk reduction. Ethn Dis 2005;15(3):365-372. 
79. Salant T, Ganschow PS, Olopade OI, Lauderdale DS. “Why take it if you don’t have anything?” 
breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med 
2006;21(7):779-785.  
80. Altschuler A, Somkin CP. Women’s decision making about whether or not to use breast cancer 
chemoprevention. Women Health 2005;41(2):81-95.  
 at U
niversity College London on D
ecem
ber 10, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
24 
81. Donnelly LS, Evans DG, Wiseman J, et al. Uptake of tamoxifen in consecutive premenopausal 
women under surveillance in a high-risk breast cancer clinic. Br J Cancer 2014;110(7):1681-1687.  
82. Keogh LA, Hopper JL, Rosenthal D, Phillips KA. Australian clinicians and chemoprevention for 
women at high familial risk for breast cancer. Hered Cancer Clin Pract 2009;7(1):9.  
83. McLay JS, Tanaka M, Ekins-Daukes S, Helms PJ. A prospective questionnaire assessment of 
attitudes and experiences of off label prescribing among hospital based paediatricians. Arch Dis 
Child. 2006;91(7):584-587.  
84. Mukattash T, Hawwa AF, Trew K, McElnay JC. Healthcare professional experiences and attitudes 
on unlicensed/off-label paediatric prescribing and paediatric clinical trials. Eur J Clin Pharmacol 
2011;67(5):449-461.  
85. Cuzick J, Sestak I, Thorat MA. Impact of preventive therapy on the risk of breast cancer among 
women with benign breast disease. Breast 2015 [Epub ahead of print]  
86. Horne R, Chapman S, Parham R, et al. Understanding patients’ adherence-related beliefs about 
medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns 
Framework. PLoS ONE 2013;8(12):e80633 
87. Karamanidou C, Weinman J, Horne R. Improving haemodialysis patients’ understanding of 
phosphate-binding medication: a pilot study of a psycho-educational intervention designed to change 
patients’ perceptions of the problem and treatment. Br J Health Psychol 2008;13(2):205-214.  
88. Zwikker HE, van den Ende CH, van Lankveld WG, et al. Effectiveness of a group-based 
intervention to change medication beliefs and improve medication adherence in patients with 
rheumatoid arthritis: a randomized controlled trial. Patient Educ Couns 2014;94(3):356-361.  
89. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence.  
Cochrane Database Syst Rev 2014;11:CD000011 
 at U
niversity College London on D
ecem
ber 10, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
25 
90. Petrie KL, Perry K, Broadbent E, Weinman J. A text message programme designed to modify 
patients' illness and treatment beliefs improves self-reported adherence to asthma preventer 
medication. Br J Health Psychol 2012;17(1):78-84. 
91. O’Carroll RE, Chambers JA, Dennis M, et al. Improving adherence to medication in stroke 
survivors: a pilot randomised controlled trial. Ann Behav Med 2013;46(3):358-368. 
92. Wu JY, Leung WY, Chang S, et al. Effectiveness of telephone counselling by a pharmacist in 
reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ 
2006;333(7567):522. 
93. Sheridan SL, Harris RP, Woolf SH. Shared decision making about screening and 
chemoprevention: a suggested approach from the U.S. Preventive Services Task Force. Am J Prev 
Med. 2004;26(1):56-66.  
94. Zikmund-Fisher BJ. The right tool is what they need, not what we have: a taxonomy of 
appropriate levels of precision in patient risk communication. Med Care Res Rev 2013;70(suppl 1):37 
- 49.  
 
 at U
niversity College London on D
ecem
ber 10, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
Figures 
Figure 1. Flow diagram of search strategy 
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Figure 2. Meta-analysis of individual-level data for preventive therapy uptake by setting 
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Table 1. Characteristics of articles reporting uptake levels of breast cancer preventive therapy 
Study Country Design Setting Agent n Age, years Uptake  
Altschuler et al., 2005 [80] USA Mixed STAR trial Tamoxifen;  raloxifene 51 40-49 (2%); 50-59 (29%); 
60-69 (35%); 70-79 (31%); 
>80 (2%) 
54.9% 
Bober et al., 2004 [28] USA Non-randomized Non-trial;  
STAR 
Tamoxifen; raloxifene 129 Mean, 52; SD, 8 25.6% (tamoxifen); 25.6% (STAR) 
Collins et al., 2013 [30] Australia Non-randomized kConFab Tamoxifen 325 Median, 37, range 18-78 0.3% (tamoxifen); 2.8% (Trial) 
Donnelley et al., 2014 [81] UK Mixed Non-trial Tamoxifen 1279 Median, 42 10.6% 
Evans et al., 2010 [52] UK Non-randomized IBIS1, IBIS2 Tamoxifen; 
Anastrozole 
2278; 
1264 
not reported 12.0% (IBIS1); 8.1% (IBIS2) 
Evans et al., 2001 [53] UK Non-randomized IBIS1; LHRH Tamoxifen; raloxifene 278; 142 not reported 11.5% (IBIS1); 9.9% (LHRH) 
Fagerlin et al., 2011 [42] USA Randomized Non-trial Tamoxifen; raloxifene 482 Mean, 62; SD, 5  0.4% 
Goldenberg et al., 2007 
[54] 
USA Non-randomized Non-trial Tamoxifen 99 Mean, 46 11.1% 
Houlihan et al., 2010 [55] USA Non-randomized STAR trial Tamoxifen; raloxifene 242 Not described 33.5% 
Juraskova et al., 2014 [71] International Randomized IBIS2 Anastrozole 290 Mean, 59 46.4% 
Kinney et al., 1998 [33] USA Non-randomized NSABP P-1 Tamoxifen 89 Mean, 59 43.8% 
Kinney et al., 1998 [56] USA Non-randomized NSABP P-1 Tamoxifen 175 Mean, 55; SD, 10 50.9% 
Korfage et al., 2013 [43] USA Randomized Non-trial Tamoxifen; raloxifene 1012 Mean, 62; SD, 6 0.3% 
Kwong et al., 2010 [57] China Non-randomized Non-trial Tamoxifen; raloxifene 26 Mean, 43; SD, 12 0% 
Loehberg et al., 2010 [37] Germany Non-randomized IBIS2 Anastrozole 2524 Mean 60; SD, 6 1.5% 
Matloff et al., 2006 [44] USA Randomized STAR trial Tamoxifen; raloxifene 48 Mean, 49 0% 
Metcalfe et al., 2008 [38] International Non-randomized Non-trial Tamoxifen; raloxifene 2677 Mean 46 5.5% (tamoxifen); 2.9% (raloxifene)  
Metcalfe et al., 2005 [59] International Non-randomized Non-trial Tamoxifen; raloxifene 81 Mean, 45 12.3% (tamoxifen); 9.9% 
(raloxifene) 
Ozanne et al., 2007 [72] USA Randomized Non-trial Tamoxifen; raloxifene 30 Control: Mean, 44; SD, 10 
vs. Intervention: Mean, 45; 
SD, 11 
2/26 7.7% 
Phillips et al., 2006 [39] International Non-randomized kConFab Tamoxifen 142 Mean, 41 0.7% 
Port et al., 2001 [60] USA Non-randomized Non-trial Tamoxifen 43 Mean, 53 4.7% 
Pujol et al., 2012 [61] France Non-randomized LIBER Letrozole 237 40-49 (36%), 50-69 (64%) 14.0% 
Razzaboni et al., 2013 [40] Italy Non-randomized IBIS II Anastrozole 471 Mean, 59 (SD, 6) 29.1% 
Rondanina et al., 2008 [62] Italy Non-randomized HOT study Tamoxifen 1457 Mean, 56 (SD, 5) 34.0% 
Taylor & Taguchi, 2005 
[63] 
Canada Non-randomized Non-trial Tamoxifen; raloxifene 88 40-49 (12%), 50-59 (20%), 
60-69 (37%), 70-80 (30%) 
6.7% 
Waters et al., 2010 [65] USA Non-randomized NHIS survey Tamoxifen 10,601; 40-79 0.2% (in 2000); 0.08% (in 2005) 
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Table 1. Characteristics of articles reporting uptake levels of breast cancer preventive therapy 
Study Country Design Setting Agent n Age, years Uptake  
10,690 
Yeomans-Kinney et al., 
1995 [66] 
USA Non-randomized NSABP P-1 Tamoxifen 232 <50 (42%), 51+ (58%) 45.3% 
Rahman & Crawford, 2009 
[67] 
USA Non-randomized Non-trial Tamoxifen 48 Median 47; IQR, 42-53 31.3% 
Metcalfe et al., 2007 [68] Canada Non-randomized Non-trial Tamoxifen; raloxifene 672 Mean, 47  6.3% (tamoxifen); 4.4% (raloxifene)  
Tchou et al., 2004 [69] USA Non-randomized Non-trial Tamoxifen 219 Mean, 47 41.6% 
Waters et al., 2012 [41] USA Non-randomized NHIS survey Tamoxifen; raloxifene 9,906; 
5,959  
35-79 (tamoxifen); 50-79 
(raloxifene) 
0.03% (2010; tamoxifen); 0.2% 
(raloxifene; 2010) 
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Table 2. Characteristics of articles reporting adherence data on breast cancer preventive therapy 
Authors Country Design Setting Agent n Age (years) Measure Follow-up 
time (years) 
Day-to-day 
adherence 
Persistence 
Cheung et al., 
2012 [29] 
International Non-
randomized 
MAP.3 Exemestane 239 Median, 61; 
IQR, 59-65 
Pill count 2 Median: 97% - 
Cuzick & 
Edwards, 1999 
[47] 
International Randomized IBIS-1 Tamoxifen 4303 Not described Pill count 1, 2, 4 - 90%; 83%; 74%  
Cuzick et al., 
2007 [70] 
International Randomized IBIS-1 Tamoxifen 7154 Mean, 51 Pill count  5 - 67.9%  
Day et al., 2001 
[31] 
USA Non-
randomized 
NSABP P-1 Tamoxifen 11064 Mean, 54; SD=9 Clinic visit 3 - 80.8% 
Day et al., 1999 
[51] 
USA Non-
randomized 
NSABP P-1 Tamoxifen 11064 Mean, 54; SD=9 Clinic visit 3 - 69.1%  
Fallowfield et 
al., 2001 [32]  
UK Non-
randomized 
IBIS1; 
TAMOPLAC 
Tamoxifen 488  Median, 46 Self-report 5 - 61.8%  
Juraskova et 
al., 2014 [71] 
International Randomized IBIS2 Anastrozole 212 Mean, 59 Self-report 3 months - 88.2%  
Klepin et al., 
2014 [34] 
USA Non-
randomized 
STAR trial Tamoxife; 
raloxifene 
1331 Mean, 67; SD, 4 Pill count Unclear,  
probably 2 
86.3%  - 
Land et al., 
2011 [35] 
USA Non-
randomized 
NSABP P-1 Tamoxifen 11064 >=60 (30%) Clinic visit 1 and 36 
months 
91%; 79%*  - 
Land et al., 
2006 [36] 
USA Non-
randomized 
STAR trial Tamoxife; 
raloxifene 
1983 35-49 (10%), 
50-59: (49%); 
60-69 (31%); 
70+ (10%) 
Clinic visit 5 - Mean: 3 years 
Maurice et al., 
2006 [58] 
UK Non-
randomized 
IBIS1 Tamoxifen 82 Not described MEMS Adherence, 
6 months; 
Persistence 5 
years 
Median % days 
correct dose: 93.2-
95.2 
79.3% 
McTieman et 
al., 2009 [48] 
USA Randomized Trial Aspirin 143 Mean, 60; SD, 6 Pill count 6 months 87%  - 
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Table 2. Characteristics of articles reporting adherence data on breast cancer preventive therapy 
Authors Country Design Setting Agent n Age (years) Measure Follow-up 
time (years) 
Day-to-day 
adherence 
Persistence 
Palva et al., 
2013 [45] 
Finland Randomized IBIS1 Tamoxifen 96 Placebo: Mean, 
50; SD, 8; 
Tamoxifen: 
Mean, 51; SD, 8 
Not 
reported 
5 - 66.7% 
Powles et al., 
1989 [73] 
UK Randomized Pilot trial Tamoxifen 200 Tamoxifen: 
Mean, 48; 
Placebo: Mean, 
49 
Self-report Months 3, 6, 
9, 12 
- 91.5%; 88.0%; 
85.5%; 84.0% 
Powles et al., 
1994 [74] 
UK Randomized Royal 
Marsden 
Tamoxifen 2012 Median, 48  Self-report 5 - 80.8% 
Powles et al., 
1998 [75] 
UK Randomized Royal 
Marsden  
Tamoxifen 2471 Median, 47 Self-report 5 - 64.5% 
Razzaboni et 
al., 2013 [40] 
Italy Non-
randomized 
IBIS II Anastrozole 471 Mean, 59; SD, 6 Pill count 6 months, 
years 1, 2, 3 
- 78.1%; 61.3%; 
41.6%; 13.9% 
Signori et al., 
2012 [49] 
USA Randomized Pilot Raloxifene; 
omega-3 
fatty acids 
46 Mean, 56-58 Pill count  1 96% - 
Veronesi et al., 
1998 [64] 
Italy Non-
randomized 
ITPS Tamoxifen 201 Median, 53 Clinic visit 5 - 73.3% 
Veronesi et al., 
1998 [25] 
International Randomized ITPS Tamoxifen 3037 Median, 51 Clinic visit 1, 2, 3, 4, 5 - 86.1%; 80.1%; 
76.2%; 74.2%; 
73.7% 
Vinayak et al., 
2013 [50] 
USA Non-
randomized 
Trial Lovastatin 30 Median, 45 Pill count 6 months - 86.7% 
Vogel et al., 
2006 [26] 
USA Randomized STAR trial Tamoxife; 
raloxifene 
19471 Mean, 59; SD, 7 Not 
reported 
4 - 68.3-71.5% 
Vogel et al., 
2010 [27] 
USA Randomized STAR trial Tamoxife; 
raloxifene 
19471 Mean, 59; SD, 7 Not 
reported 
5 - 61.1-72.6% 
RCT-SS, Randomised Controlled Trial Sub-Study; * Reports a combined adherence and persistence measure; ITPS, Italian Tamoxifen Prevention Study 
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Table 3. Characteristics of qualitative studies discussing breast cancer preventive therapy decision-making 
Study Country Design Analysis Setting Agent n Age, years (% of sample) 
Altschuler et al., 2005 [80] USA Mixed Grounded theory STAR Tamoxifen;  raloxifene 51 40-49 (2%); 50-59 (29%); 60-69 (35%); 
70-79 (31%); >80 (2%) 
Cyrus-David et al., 2001 [76] USA Qualitative Cross-case analysis using variable-
oriented strategies 
Non-trial Tamoxifen;  raloxifene 26 30-59 (54%); >=60 (42%); unknown 
(4%) 
Donnelley et al., 2014 [81] UK Mixed Framework analysis Non-trial Tamoxifen 30 Median, 42 
Heisey et al., 2006 [77] Canada Qualitative Framework analysis Non-trial; STAR  Tamoxifen; raloxifene 27 Median, 61  
Holmberg et al., 2010 [46] USA Qualitative Narrative theory STAR  Tamoxifen 2 73 and 52 
Paterniti et al., 2005 [78] USA Qualitative Unclear, likely to be thematic Non-trial Tamoxifen 27 68.3 years (61-78) 
Salant et al., 2006 [79] USA Qualitative Grounded theory Non-trial Tamoxifen 33 Mean 55 (range, 33-70) 
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Clinical factors               
     Family member diagnosed       -   -    - 
     First-degree relative diagnosed -              
     First-degree relative died -              
     History breast biopsy -             - 
     Abnormal breast biopsy               
     Family history of stroke -              
     Family history cataracts -              
     Regular physician       -        
     Physician recommendation               
     Physician helped me understand               
     Physician answered all my questions               
     Having annual physical       -        
     Objective risk       -    -    
     No BRCA mutation               
     Menopausal status            -  - 
     Hysterectomy       -     -  - 
     HRT/Oestrogen use†           X    
     Experience of hot flashes       -        
Patient factors               
     Concerned about side-effects*      -         
     Concerned that oestrogen contraindicated                
     Believe that medication won’t prevent cancer       -        
     Intrusive thinking               
     Depression -          -    
     Anxiety           -    
     Life orientation -              
     Autonomy -              
     Knowledge of breast cancer       -        
     Perceived risk (not described)       -        
     Perceived risk (vulnerability)               
     Perceived risk (absolute)           -    
     Perceived risk (relative)           -    
     Perceived risk (numerical)           -    
Table 4. Summary of factors affecting uptake of breast cancer preventive therapy 
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     Worry about breast cancer               
     Peace of mind       -        
     Concern about possibility of placebo      -         
     Experimental nature of trial               
     Perceived expertise of clinician     -          
     Personal desire to participate               
     Perceived value of trial               
     Perceived inconvenience of trial               
     Need to take a pill every day            -   
     Frequency of clinic visits               
     Travel time to clinic            -   
     Body Mass Index           -    
     Smoking           -    
     Alcohol consumption (low)               
     Physical activity            -    
     Illegal drug use           -    
     Prior use of screening       -        
     Significant others reassured      -         
     Self-reported health       -        
Demographic factors               
     Older age       -   -  X   
     Race       -        
     Country               
     Marital status      -    -  -   
     Education       -   - - -   
     Income            -   
     Employment            -   
     Insurance       -     -   
     Cost      - -        
     Parity              - 
Note: - Tested, but not statistically significant;   Tested in univariable analyses, and significant;  Tested multivariable, and significant; X significant in opposite of hypothesised direction; * Yeomans-Kinney and 
colleagues (1995) tested multiple different concerns about side-effects, the results of which were mixed; †Rondanina and colleagues (2008) purposively sampled women who were currently taking or considering HRT 
for menopausal symptoms.  
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Clinical factors            
     Placebo vs. tamoxifen (tamoxifen lower)        -    
     Raloxifene vs. tamoxifen (tamoxifen lower)            
     Higher objective risk      -      
     Presence of diabetes   -         
     Presence of heart disease   -         
     Presence of impaired vision   -         
     Less depression      -      
     Diagnosis of prior malignancy   -         
     Comorbid condition    -        
     Taking other medications   -         
     Hysterectomy      -      
     Menopausal status      - -     
     Previous breast biopsy      -      
Patient factors            
     Longer expected time on treatment            
     Cognitive ability*   -         
     Alcohol consumption    -        
     Non-smoker            
     Overweight / obese    -        
     Physical activity    -        
Demographic factors            
     Younger age      -      
     Ethnicity   - -        
     More education   -         
     Employment    -        
     Income    -        
     Living alone    -        
     Marital status      -      
     Parity      -      
Note: - Tested, but not statistically significant;  Tested in univariable analyses, and significant; Tested in multivariable analyses, and significant; *Keplin and colleagues tested multiple different cognitive abilities 
and only verbal fluency () and verbal fluency were significant ().  
 
Table 5. Summary of factors affecting adherence to breast cancer preventive therapy 
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Table 6. Qualitative themes affecting decision-making and uptake of preventive therapy 
 Risk Side effects Knowledge Medication concerns Information Trial- issues Other 
Altschuler et 
al., 2005 [80] 
Perceived personal risk;  threat 
of other disease 
Side-effect 
concerns 
 Concern about 
contraindication of HRT 
 Altruism; time; 
commitment; 
randomization 
 
Cyrus-David 
et al., 2001 
[76] 
Accuracy of risk perceptions;  
perceived wellness 
 Knowledge of risk 
factors; awareness of 
chemoprevention 
drug interactions; 
chemical properties of 
drugs; length of 
treatment 
Patient-provider 
communication 
 distrust of medical 
system; conception 
issues; cost 
Donnelley et 
al., 2014 [81] 
Daily reminder of risk Side-effect 
concerns 
 tamoxifen as a ‘cancer 
drug 
  impact of others’ 
experience 
Heisey et al., 
2006 [77] 
Perceived personal risk;  denial 
of risk; expectations for risk-
reduction 
Side-effect 
concerns 
 Aversion to medication;  
HRT controversies 
Lack of 
information; 
information 
sources 
Altruism;  Being in control;  term 
‘chemoprevention’; cost 
Holmberg et 
al., 2010 [46] 
The meaning of ‘risk’;  
personalised risk assessments; 
concern about possible 
diagnosis;  comparisons with 
coronary heart risk 
      
Paterniti et 
al., 2005 [78] 
Perceived personal risk; 
alternative approaches to 
reducing risk 
  Risks and benefits of 
tamoxifen 
  Meaning of breast 
cancer; religiosity 
Salant et al., 
2006 [79] 
Perceived personal risk; Lack of 
symptoms/problems 
 Mythical causes of 
breast cancer 
Dislike of medication; 
use of medication to 
treat rather than prevent 
  Cognitive avoidance of 
cancer  
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